Banales J M, Marin J J G, Lamarca A, et al. Cholangiocarcinoma2020: the next horizon in mechanisms and management[J]. Nat RevGastroenterol Hepatol, 2020, 17(9): 557-588.
Krasinskas A M. Cholangiocarcinoma[J]. Surg Pathol Clin, 2018,11(2): 403-429.
Rizvi S, Khan S A, Hallemeier C L, et al. Cholangiocarcinomaevolving concepts and therapeutic strategies[J]. Nat Rev ClinOncol , 2018, 15(2): 95-111.
Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliarytract cancer[J]. Nat Genet, 2015, 47(9): 1003-1010.
Blechacz B. Cholangiocarcinoma: current knowledge and newdevelopments[J]. Gut Liver, 2017, 11(1): 13-26.
Valle J W, Wasan H, Lopes A, et al. Cediranib or placebo incombination with cisplatin and gemcitabine chemotherapy forpatients with advanced biliary tract cancer (ABC-03): a randomisedphase 2 trial[J]. Lancet Oncol, 2015, 16(8): 967-978.
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatinwith or without cetuximab in advanced biliary-tract cancer (BINGO):a randomised, open-label, non-comparative phase 2 trial[J/OL].Lancet Oncol, 2014, 15(8): 819-828.
Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signalingin cancer[J]. Clin Cancer Res, 2015, 21(12): 2684-2694.
Jr Roskoski R. The role of fibroblast growth factor receptor (FGFR)protein tyrosine kinase inhibitors in the treatment of cancersincluding those of the urinary bladder[J]. Pharmacol Res, 2020,151:104567[2020-09-11]. https://pubmed.ncbi.nlm.nih.gov/31770593/.Doi: 10.1016/j.phrs.2019.104567.
Moeini A, Sia D, Bardeesy N, et al. Molecular pathogenesis andtargeted therapies for intrahepatic cholangiocarcinoma[J]. ClinCancer Res, 2016, 22(2): 291-300.
Dabney R S, Khalife M, Shahid K, et al. Molecular pathwaysand targeted therapy in cholangiocarcinoma[J]. Clin Adv HematolOncol, 2019, 17(11): 630-637.
Abou-Alfa G K, Sahai V, Hollebecque A, et al. Pemigatinibfor previously treated, locally advanced or metastaticcholangiocarcinoma: a multicentre, open-label, phase 2 study[J].Lancet Oncol, 2020, 21(5): 671-684.
Valle J, Wasan H, Palmer D H, et al. Cisplatin plus gemcitabineversus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010,362(14): 1273-1281
Javle M, Lowery M, Shro R T, et al. Phase II study of BGJ398 inpatients with FGFR-altered advanced cholangiocarcinoma[J]. J ClinOncol, 2018, 36(3): 276-282.
Krook M A, Lenyo A, Wilberding M, et al. Efficacy of FGFRinhibitors and combination therapies for acquired resistance inFGFR2-fusion cholangiocarcinoma[J]. Mol Cancer Ther, 2020,19(3): 847-857.
Goyal L, Shi L, Liu L Y, et al. TAS-120 overcomes resistance toATP-competitive FGFR inhibitors in patients with FGFR2 fusionpositive intrahepatic cholangiocarcinoma[J]. Cancer Discov, 2019,9(8): 1064-1079.
Krook M A, Bonneville R, Chen H Z, et al. Tumor heterogeneity andacquired drug resistance in FGFR2-fusion-positive cholangiocarcinomathrough rapid research autopsy[J/OL]. Cold Spring Harb Mol CaseStud, 2019, 5(4): a004002[2020-09-11]. https://www.researchgate.net/publication/334837135_Tumor_heterogeneity_and_acquired_drug_resistance_in_FGFR2-fusion-_positive_cholangiocarcinoma_through_rapid_research_autopsy. Doi: 10.1101/mcs.a004002.
Goyal L, Liu L Y, Lennerz J K, et al. Abstract LB-092: TAS120, acovalently-binding FGFR inhibitor (FGFRi), overcomes resistance toBGJ398 in patients with FGFR2 fusion positive cholangiocarcinoma[J/OL]. Cancer Res, 2018, 78(Suppl 13): LB-092[2020-09-11]. https://www.researchgate.net/publication/327083782_Abstract_LB-092_TAS120_a_covalently-binding_FGFR_inhibitor_FGFRi_overcomes_resistance_to_BGJ398_in_patients_with_FGFR2_fusion_positive_cholangiocarcinoma. Doi: 10.1158/1538-7445.AM2018-LB-092.
Kheder S I, Hong D S. Emerging targeted therapy for tumors withNTRK fusion proteins[J]. Clin Cancer Res, 2018, 24(23): 5807-5814.
Farago A F, Demetri G D. Larotrectinib, a selective tropomyosinreceptor kinase inhibitor for adult and pediatric tropomyosinreceptor kinase fusion cancers[J]. Future Oncol, 2020, 16(9): 417-425.
Ross J S, Wang K, Gay L, et al. New routes to targeted therapyof intrahepatic cholangiocarcinomas revealed by next-generationsequencing[J]. Oncologist, 2014, 19(3): 235-242.
Scott L J. Larotrectinib: first global approval[J]. Drugs, 2019, 79(2):201-206.
Drilon A E, Farago A F, Tan D S W, et al. Activity and safety oflarotrectinib in adult patients with TRK fusion cancer: an expandeddata set[J/OL]. J Clin Oncol, 2020, 38(suppl 15): 3610[2020-09-11]. https://www.researchgate.net/publication/341629284_Activity_and_safety_of_larotrectinib_in_adult_patients_with_TRK_fusion_cancer_An_expanded_data_set. Doi 10.1200/JCO.2020.38.15_suppl.3610.
Gu T L, Deng X X, Huang F Z, et al. Survey of tyrosinekinase signaling reveals ROS kinase fusions in humancholangiocarcinoma[J/OL]. PLoS One, 2011, 6(1): e15640[2020-09-11]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015640.
Javle M, Churi C, Kang H S C, et al. HER2/neu-directed therapyfor biliary tract cancer[J/OL]. J Hematol Oncol, 2015, 8: 58[2020-09-11]. https://pubmed.ncbi.nlm.nih.gov/26022204/. Doi: 10.1186/s13045-015-0155-z.
Yang H, Ye D, Guan K L, et al. IDH1 and IDH2 mutations intumorigenesis: mechanistic insights and clinical perspectives[J].Clin Cancer Res, 2012, 18(20): 5562-5571.
Tsukada Y I, Fang J, Erdjument-Bromage H, et al. Histonedemethylation by a family of JmjC domain-containing proteins[J].Nature, 2006, 439(7078): 811-816.
Rizvi S, Gores G J. Emerging molecular therapeutic targets forcholangiocarcinoma[J]. J Hepatol, 2017, 67(3): 632-644.
Lowery M A, Burris H A, Janku F, et al. Safety and activity ofivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma:a phase 1 study inhibitor[J]. Lancet Gastroenterol Hepatol, 2019, 4(9):711-720.
Abou-Alfa G K, Macarulla T, Javle M M, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy):a multicentre, randomised, double-blind, placebo-controlled, phase3 study[J]. Lancet Oncol, 2020, 21(6): 796-807.
Harding J J, Lowery M A, Shih A H, et al. Isoform switchingas a mechanism of acquired resistance to mutant isocitratedehydrogenase inhibition[J/OL]. Cancer Discov, 2018, 8(12): 1540-1547.
Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specificimmunohistochemistry reveals low mutation rates in biliary tractcancer and restriction to intrahepatic cholangiocarcinoma[J]. ModPathol, 2014, 27(7): 1028-1034.
Hyman D M, Puzanov I, Subbiah V, et al. Vemurafenib in multiplenonmelanoma cancers with BRAF V600 mutations[J]. N Engl JMed, 2015, 373(8): 726-736.
Prahallad A, Sun C, Huang S D, et al. Unresponsiveness of coloncancer to BRAF(V600E) inhibition through feedback activation ofEGFR[J]. Nature, 2012, 483(7387): 100-103.
Lavingia V, Fakih M. Impressive response to dual BRAF andMEK inhibition in patients with BRAF mutant intrahepaticcholangiocarcinoma-2 case reports and a brief review[J]. JGastrointest Oncol, 2016, 7(6): E98-E102.
Wainberg Z A, Lassen U, Elez E, et al. Efficacy and safety ofdabrafenib (D) and trametinib (T) in patients (pts) with BRAFV600E-mutated biliary tract cancer (BTC): a cohort of the ROARbasket trial[J/OL]. J Clin Oncol, 2019, 37(Suppl 4): 187[2020-09-11]. https://www.researchgate.net/publication/330805020_Efficacy_and_safety_of_dabrafenib_D_and_trametinib_T_in_patients_pts_with_BRAF_V600E-mutated_biliary_tract_cancer_BTC_A_cohort_of_the_ROAR_basket_trial. Doi: 10.1200/JCO.2019.37.4_suppl.187.
Golan T, Raitses-Gurevich M, Kelley R K, et al. Overallsurvival and clinical characteristics of BRCA-associatedcholangiocarcinoma: a multicenter retrospective study[J].Oncologist, 2017, 22(7): 804-810.
Fouassier L, Marzioni M, Afonso M B, et al. Signalling networks incholangiocarcinoma: molecular pathogenesis, targeted therapies anddrug resistance[J]. Liver Int, 2019, 39 (Suppl 1): 43-62.
Wang W W, Zhong W, Yuan J H, et al. Involvement of Wnt/β-cateninsignaling in the mesenchymal stem cells promote metastatic growthand chemoresistance of cholangiocarcinoma[J]. Oncotarget, 2015,6(39): 42276-42289.
Goyal L, Zheng H, Yurgelun M B, et al. A phase 2 andbiomarker study of cabozantinib in patients with advancedcholangiocarcinoma[J]. Cancer, 2017, 123(11): 1979-1988.
Pant S, Saleh M, Bendell J, et al. A phase I dose escalation studyof oral c-MET inhibitor tivantinib (ARQ 197) in combination withgemcitabine in patients with solid tumors[J]. Ann Oncol, 2014,25(7): 1416-1421.